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Guillain-Barré syndrome (GBS) is a rapidly evolving neuropathy that often occurs after an acute 
infection.1  The majority of patients become severely disabled and unable to walk within a few days 
with approximately 20-30% of them require assisted ventilation. Up to 5-10% of the patients die 
during the course of the disease for pneumonia, cardiac or thromboembolic complications. GBS is a 
monophasic disorder that spontaneously stabilize within 2-3 weeks and subsequently progressively 
recover. Since the introduction of assisted ventilation, between 50% to  70% of the patients 
(depending on the need of artificial ventilation) recovered an independent ambulation within 6 
months with only supportive therapy.2 
GBS is an auto immune disease caused by an attack of the immune system against the nerve 
triggered by an infective agent deemed to share  a molecule with nerve.3  This has led to the use of 
immune therapies, and there is now evidence from controlled studies that plasma exchange and 
intravenous immunoglobulins (IVIg) improve the prognosis of GBS and patients’ disability 
compared to standard supportive therapy.4, 5 Despite this, almost 20% of the patients remain 
disabled after 6 month even if several patients may continue to recover, even if often incompletely, 
for 2-3 years.  Several attempts have been made to further improve the prognosis of GBS including 
treatment with interferon, the association of steroids to IVIg but none of them proved to be effective 
in controlled studies. 
In the last years, pathological and experimental studies have shown that complement may play a 
pivotal role in causing nerve damage in GBS especially when the disease is associated with 
antibodies against the ganglioside GM1. 6, 7 This was also evident in animal models of GBS where 
treatment with the monoclonal antibody eculizumab directed against the fraction C5 of complement 
was effective in improving the neuropathy.8 Given the previously reported benefit of this therapy in 
two complement-mediated disorders,  paroxysmal nocturnal hemoglobinuria and atypical hemolytic 
uremic syndrome, it was postulated that early treatment with eculizumab in GBS might prevent or 
block the damage caused by anti-nerve antibodies and improve  the outcome of the patients. 
In this issue, Misawa et al report the results of a placebo-controlled study with eculizumab in 34 
patients with severe GBS treated with IVIg.9 Patients were treated before or during IVIg treatment 
that was started within 2-12 days from disease onset.  Given the unbalance between the number of 
treated (23 patients) and untreated patients (11 patients) the statistical analysis of response to 
therapy  was based on an historical control group of 62 GBS patients.10 The study failed to reveal a 
significant effect of eculizumab on the primary outcome, i.e. the proportion of patients able to walk 
independently for 5 meters within 4 weeks (29 days) from disease onset. Even if there was a certain 
degree of improvement in the eculizumab treated patients in this and in some secondary endpoints, 
the main significant difference in favor of eculizumab  was the proportion of patients who 
completely recovered or became able to run after 24 weeks. 
The main limit of this study is the relatively small number of patents examined and the absence of a 
direct comparison with a control group, also because the historical control group had a lower degree 
of disability. It would be also interesting to compare the results in relation to the start of eculizumab 
treatment since  it is possible that its efficacy may vary if given early in the disease (say within 2-4 
days) when there is the initial effect of complement, or after a week when the nerve might be 
already damaged.  
The importance of this study relies on the fact that it is based on the evidence that GBS is a 
complement-mediated disease induced by antibodies against nerve antigens. This has been clearly 
shown in patients with antibodies to gangliosides and particularly GM1 and GD1a or their 
complexes where they are triggered by an antecedent infection by certain strains of campylobacter 
jejuni bearing a cross-reactive surface antigen.3 This reactivity has been shown however to occur in 
no more than 30-40% of the patients. It is possible that the same mechanism may also occur in 
patients bearing other, so far unidentified antibodies, but  this needs to elucidated.7  In any case, in 
this study the response to therapy was not different between patients with or without anti-
ganglioside antibodies or with or without the axonal form of GBS that is often associated with this 
reactivity. 
Even if this was mainly a negative study, some data may indicate that this therapy may lead to a 
more frequent complete  recovery over six months. This should  be confirmed in a large randomized 
controlled studies even if the extremely high cost of eculizumab and the not so clear results deriving 
from this study might require a better identification of the characteristics of the patients to be 
included.   
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